Nonclinical toxicology study of recombinant-plasmid DNA anti-rabies vaccines

Vaccine

Volumn 24, Issue 15, 2006, Pages 2790-2798

  Kumar, P Uday ^a   Kumar, B Dinesh ^a   Annapurna, V V ^a   Krishna, T Prasanna ^a   Kalyanasundaram, S ^a   Suresh, P ^a   Harishankar, N ^a   Jagadeesan, V ^a   Hariharan, S ^a   Naidu, A Nadamuni ^a   Krishnaswamy, Kamala ^a   Rangarajan, P N ^b   Srinivasan, V A ^c   Reddy, G S ^c   Sesikeran, B ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c Indian Immunologicals Limited   (India)

Author keywords

Abhayrab; Biotech products; Combination rabies vaccine (CRV); DNA rabies vaccine (DRV); Pre clinical toxicology; Safety evaluation; Toxicology

Indexed keywords

DNA VACCINE; PLASMID DNA; RABIES VACCINE; RECOMBINANT VACCINE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; IMMUNOTOXICITY; MALE; MOUSE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; RECOMBINANT PLASMID; TOXICITY TESTING;

ACUTE TOXICITY TESTS; ANIMALS; FEMALE; MALE; MICE; RABIES VACCINES; TOXICITY TESTS, CHRONIC; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 33644901750     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.01.002     Document Type: Article

References (25)

1. C. Bahloul, Y. Jacob, N. Tordo, and P. Perrin DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses Vaccine 16 1998 417 425
2. Biotech Consortium India Limited and Department of Biotechnology, GOI, National Consultation on Biosafety aspects related to genetically modified organisms, India, 2004.
3. S. Biswas, A.P. Kalanidhi, M.S. Ashok, G.S. Raddy, V.A. Srinivasan, and P.N. Rangarajan Evaluation of rabies virus neutralizing antibody titres induced by intramuscular inoculation of rabies DNA vaccine in mice and Bonnet monkeys Indian J Exp Biol 39 2001 533 536
4. S. Biswas, G.S. Reddy, V.A. Srinivasan, and P.N. Rangarajan Preexposure efficacy of a Novel Combination DNA and inactivated rabies virus vaccine Human Gene Ther 12 2001 1917 1922
5. S. Biswas, M.S. Ashok, G.S. Reddy, V.A. Srinivasan, and P.N. Rangarajan Evaluation of the protective efficacy of a rabies DNA vaccine in mice using an intracerebral challenge model Curr Sci 76 1999 1012 1016
6. G.L. Cockerell, C.S. Aaron, and J.B. Moe Commentary: redesigning the pre-clinical paradigm: the role of pathology and toxicology in supporting discovery research Toxicol Pathol 27 1999 477 478
7. Drug and Cosmetics (Eighth Amendment Rules 1988 of Drug and Cosmetic Act)) Act, of 1940. Schedule Y Govt. of India. Drug Controller General of India; Requirement and guidelines of clinical trials or import and manufacture of new drug, 2002.
8. FDA, 1997a. Guidelines for industry and reviews repeal of section 507 of Federal Food, Drug and Cosmetic Act, USA (http://www.fda.gov/cder/guidance/ index.htm ).
9. FDA, 1997b. Points to consider in the manufacturing and testing of monoclonal antibody; products for human use. Federal Food, Drug and Cosmetic Act, USA.
10. D.B. Fishbein, L.E. Robinson, and N. Rabies Engl J Med 329 1993 1632 1638
11. Z.F. Fu Rabies and rabies research: past, present and future Vaccine 15 1997 S20 S24
12. B. Genton, F. Al yaman, I. Betuela, R.F. Anders, A. Saul, and K. Baea Safety and immunogenicity of a three component blood stage malaria vaccine (MSP1, MSP2 RESA) against plasmodium falciparum in Papua New Guinea children Vaccine 22 2003 30 41
13. N.A. Horn, J.A. Meek, G. Budahazi, and M. Marquet Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials Hum Gene Ther 6 5 1995 565 573
14. ICH, International Conference on Harmonization, Safety steps 4/S documents Buffalo Grove 12, Interpharma press, 1997.
15. ICH, Preclinical safety evaluation of biotechnology derived pharmaceuticals, 1997.
16. Paget, GE, Barnes, JM. Evaluation of drug activities. In: Laurence DR, Bacharach AL., editors. Pharmacometrics, vol. 1, London, Academic Press; 1964.
17. J.C. Petricciani Recombinant DNA vaccines and therapeutics Lancet 342 1993 1067 1068
18. N.B. Ray, L.C. Ewalt, and D.L. Lodmell Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection Vaccine 15 1997 892 895
19. G. Sampath, S.V. Reddy, M.L. Rao, Y.U. Rao, and C. Palaniappan An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India Vaccine 23 7 2005 897 900
20. M.S. Tullu, S. Rodrigues, M.N. Muranjan, S.B. Bavdekar, J.R. Kamat, and P.R. Hira Neurological complications of rabies vaccines Indian Pediatr 40 2003 150 154
21. US Department of Health and Human Sciences, FDA (CDER) (2001) Immunotoxicology Evaluation of Investigational New Drug G.3010 DFT. Doc, http://www.fda.gov/cder/guidance/index.htm.
22. Warner GL, Haggerty HG. Immunotoxicology of recombinant DNA derived therapeutic proteins. In: Comprehensive Toxicology, vol. 5, Lawrence DA, editor. Toxicology of the Immune System. NY, USA: New York State Dept. of Health; 1997.
23. J. Weissnger Preclinical pharmacology and toxicology of haemopoitic factors Biotech Advances 7 1989 387 399
24. Z. Xiang, and H.C.J. Ertl Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines Immunity 2 1995 129 135
25. Z.Q. Xiang, S. Spitalnik, M. Tran, J. Cheng, and H.C.J. Ertl Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus Virology 199 1994 132 140